外周血单个核细胞EBV-DNA在非霍奇金淋巴瘤预后监测中的临床应用价值*

doi:10.3969/j.issn.1671-2587.2021.03.014

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (3): 350-359.DOI: 10.3969/j.issn.1671-2587.2021.03.014

外周血单个核细胞EBV-DNA在非霍奇金淋巴瘤预后监测中的临床应用价值^*

张扬, 戴春阳, 华艳, 陈少华, 陈兆武, 李明

230031 中国科技大学附属第一医院西区（安徽省肿瘤医院）检验科

收稿日期:2020-12-04 出版日期:2021-06-20 发布日期:2021-06-22
通讯作者: 李明,男,副主任技师,博士,主要从事肿瘤免疫治疗的液态活检方面研究,（E-mail）liming19831002@163.com。
作者简介:张扬（1986-）,女,安徽淮南人,主治医师,硕士,主要从事肿瘤的分子及个体化检测方面研究,（E-mail）zhangyang_0912@163.com。
基金资助:
*本课题受安徽省自然科学基金面上项目（No.006162982003）资助

Epstein-Barr Virus DNA Load in Peripheral Blood Mononuclear Cells to Evaluate the Prognosis for non-Hodgkin's Lymphoma

ZHANG Yang, DAI Chun-yang, HUA Yan, et al

Department Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China（Anhui Provincial Cancer Hospital）, Hefei 230031

Received:2020-12-04 Online:2021-06-20 Published:2021-06-22

摘要/Abstract

摘要： 目的分析不同临床特征的非霍奇金淋巴瘤（Non-Hodgkin's lymphoma,NHL）患者外周血单个核细胞EB病毒DNA（Epstein-Barr virus DNA,EBV-DNA）载量的差异,探讨其在监测患者预后中的临床应用价值。方法回顾性分析2017年4月~2020年9月在中国科技大学附属第一医院西区就诊的421例非霍奇金淋巴瘤患者的EBV-DNA在不同年龄、性别、病理类型、临床分期、淋巴瘤B症状、预后指数IPI、临床常见检测指标等方面的差异。分析连续定期随访的97例NHL患者治疗前后的EB病毒载量变化,讨论EBV-DNA在患者预后中的意义。结果 421例NHL患者外周血单个核细胞EBV-DNA阳性率为41.8%,阳性率随着患者年龄增加而不断增高,其中T和NK细胞来源的以及有淋巴瘤B症状的NHL患者更易受感染,且不同组织来源的NHL患者感染率也有明显差异。97例随访NHL患者按照IPI分为四组,低危组、低中危组和高中危组治疗后EBV-DNA载量明显下降,而高危组治疗后载量无明显变化。EB病毒感染后的NHL患者前白蛋白、白蛋白、视黄醇结合蛋白明显低于未感染者,且风险较高,生存时间较短。临床指标中病理类型、EBV感染、淋巴瘤B症状、有无骨髓浸润、PA和CysC与预后显著相关,其中病理类型、EBV感染、有无骨髓浸润和CysC是NHL的独立预后因素,成熟T和NK细胞来源NHL患者预后更差。结论不同类型NHL患者外周血单个核细胞中EBV-DNA载量具有差异,治疗前后定期检测患者EB病毒载量变化对预后监测有一定的临床应用价值。

关键词: EB病毒DNA, 非霍奇金淋巴瘤, 临床特征, 预后

Abstract: Objective To analyze the differences of Epstein-Barr virus (EBV) DNA in peripheral blood mononuclear cells (PBMCs) of patients with non-Hodgkin's lymphoma (NHL), and to discuss its clinical applications in prognosis. Methods A retrospective analysis of 421 NHL patients from the Western Branch of the First Affiliated Hospital of University of Science and Technology of China between April 2017 and September 2020 were conducted. The following clinical information was collected: age, sex, pathological type, clinical stage, lymphoma B symptoms, NHL international prognostic index (IPI), the results of blood routine and biochemical. Ninety-seven NHL patients were followed up regularly to analyze the changes of EBV DNA load before and after treatment to discuss its significance in the prognosis. Results The positive rate of EBV DNA from PBMCs in 421 NHL patients was 41.8%. The EBV DNA positive rate increased with age. Among them, NHL patients with T and NK cells and with lymphoma B symptoms were more susceptible to EBV infection, and the infection rate of patients with different tissue sources was also significantly different.According to International prognostic index, 97 NHL patients were divided into four groups. After treatment, EBV DNA load in the low-risk group, low-medium-risk group and middle-risk group decreased significantly, while the load in the high-risk group did not change significantly. The prealbumin(PA), albumin(ALB), and retinol binding protein (RBP) in NHL patients after EBV infection are significantly lower than those in uninfected patients, and the risk was higher and the survival time was shorter. Among the clinical indicators, pathological types, EBV infection, lymphoma B symptoms, bone marrow infiltration, PA and CysC were significantly correlated with the prognosis of patients. And pathological types, EBV infection, bone marrow infiltration and CysC were found to be independent prognostic factors in NHL. Patients with NHL derived from mature T and NK cells had poor prognosis. Conclusion Different types of NHL patients had differences in EBV DNA in PBMCs. Regular EBV DNA load monitoring before and after therapy could be clinical application value for prognosis monitoring.

Key words: Epstein-Barr virus DNA, Non-Hodgkin's lymphoma, Clinical features prognosis

中图分类号:

R733

张扬, 戴春阳, 华艳, 陈少华, 陈兆武, 李明. 外周血单个核细胞EBV-DNA在非霍奇金淋巴瘤预后监测中的临床应用价值^*[J]. 临床输血与检验, 2021, 23(3): 350-359.

ZHANG Yang, DAI Chun-yang, HUA Yan, et al. Epstein-Barr Virus DNA Load in Peripheral Blood Mononuclear Cells to Evaluate the Prognosis for non-Hodgkin's Lymphoma[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(3): 350-359.

参考文献

[1] MARQUES-PIUBELLI M L,SALAS Y I,PACHAS C,et al.Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas:a review[J].Pathology,2020,52(1):40-52.
[2] KOSTADINOVA T,IVANOVA L I,TODOROVA T T,et al.Detection of EBV DNA in non-Hodgkin lymphoma patients in Bulgaria[J].Indian J Hematol Blood Transfus,2019,35(3):465-470.
[3] SWERDLOW S H,CAMPO E,PILERI S A,et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood.2016,127(20):2375-2390.
[4] HORWITZ S M,ZELENETZ A D,GORDON L I,et al.NCCN Guidelines Insights:Non-Hodgkin's Lymphomas, Version 3.2016.[J] Natl Compr Canc Netw.2016,14(9):1067-1079.
[5] 宋佳琳,魏小磊,张元坤,等.IPI、NCCN-IPI及年龄调整的IPI评分系统在弥漫大B细胞淋巴瘤患者中的预后价值比较[J].中华血液学杂志,2018,39(9):739-744.
[6] VERMA N,PATEL S,OSBORN V,et al.Prognostic significance of human papillomavirus and Epstein-Bar virus in nasopharyngeal carcinoma[J].Head Neck,2020,42(9):2364-2374.
[7] BAKKALCI D,JIA Y M,WINTER J R,et al.Risk factors for Epstein Barr virus-associated cancers:a systematic review,critical appraisal,and mapping of the epidemiological evidence[J].J Glob Health,2020,10(1):010405.
[8] OKAMOTO A,YANADA M,INAGUMA Y,et al.The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients[J].Hematol Oncol,2017,35(1):87-93.
[9] 王克迪,吕治,高琰,等.外周血单个核细胞中和血浆中EB病毒核酸载量的对比分析[J].中华检验医学杂志,2018,41(10):755-758.
[10] CHEN Y,ZHENG X Y,CHEN B Y,et al.The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma[J].Leuk Lymphoma,2017,58(10):2349-2355.
[11] 朱悦红,孟文静,何丽宏,等.原发性乳腺弥漫大B细胞淋巴瘤的预后分析[J].中华肿瘤杂志,2019,41(3):235-240.
[12] PEI Y G,WONG J H Y,ROBERTSON E S.Targeted therapies for Epstein-Barr virus-associated lymphomas[J].Cancers (Basel),2020,12(9):E2565.
[13] WANG J,ZHOU M,XU J Y,et al.Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP[J].Medicine (Baltimore),2016,95(38):e4893.
[14] TAN K M,CHIA B,LIM J Q,et al.A clinicohaematolog
ical prognostic model for nasal-type natural killer/T-cell lymphoma:a multicenter study[J].Sci Rep,2019,9(1):14961.
[15] COHEN M,VISTAROP A G,HUAMAN F,et al.Cytotoxic response against Epstein Barr virus coexists with diffuse large B-cell lymphoma tolerogenic microenvironment:clinical features and survival impact[J].Sci Rep,2017,7(1):10813.
[16] 胡歌,王先火,张会来.红细胞分布宽度在外周T细胞淋巴瘤非特指型患者预后评估中的价值[J].山东医药,2020,60(16):62-65.
[17] PENG J H,LI H,OU Q J,et al.Preoperative lymphocyte-to-monocyte ratio represents a superior predictor compared with neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios for colorectal liver-only metastases survival[J].Onco Targets Ther,2017,10:3789-3799.
[18] TAN K M,CHIA B,LIM J Q,et al.A clinicohaematolog
ical prognostic model for nasal-type natural killer/T-cell lymphoma:a multicenter study[J].Sci Rep,2019,9(1):14961.
[19] CALERO-PANIAGUA I,RUÍZ-CHICOTE A M,NIETO-RODRÍGUEZ J A,et al.Usefulness of cystatin C as a prognostic marker in venous thromboembolism[J].Med Clin (Barc),2014,143(12):530-534.
[20] JI F,ZHANG S Q,JIANG X,et al.Diagnostic and prognostic value of galectin-3,serum creatinine,and cystatin C in chronic kidney diseases[J].J Clin Lab Anal,2017,31(5):e22074.
[21] GUO R,ZHANG Y C,TENG M X,et al.DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression[J].Nat Microbiol,2020,5(8):1051-1063.
[22] NAVARI M,FULIGNI F,LAGINESTRA M A,et al.Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus[J].Front Microbiol,2014,5:728.
[23] VERMA D,CHURCH T M,SWAMINATHAN S.Epstein-Barr virus co-opts TFIIH component XPB to specifically activate essential viral lytic promoters[J].Proc Natl Acad Sci USA,2020,117(23):13044-13055.
[24] MURER A,RÜHL J,ZBINDEN A,et al.Erratum for murer et al.,“MicroRNAs of Epstein-Barr virus attenuate T-cell-mediated immune control in vivo”[J].mBio,2019,10(4):e01482-19.
[25] KIM S J,HYEON J,CHO I,et al.Comparison of efficacy of pembrolizumab between Epstein-Barr viruspositive and negative relapsed or refractory non-Hodgkin lymphomas[J].Cancer Res Treat,2019,51(2):611-622.
[26] BALFOUR H H JR,SCHMELING D O,GRIMM-GERIS J M.The promise of a prophylactic Epstein-Barr virus vaccine[J].Pediatr Res,2020,87(2):345-352.

外周血单个核细胞EBV-DNA在非霍奇金淋巴瘤预后监测中的临床应用价值^*

Epstein-Barr Virus DNA Load in Peripheral Blood Mononuclear Cells to Evaluate the Prognosis for non-Hodgkin's Lymphoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	迟红旭, 江颖, 姚欢, 田静, 李玲玲, 朱晓君, 刘晓敏, 张雷英, 孙桂香, 于洋. 非霍奇金淋巴瘤患者行外周血单个核细胞采集前后血细胞的变化及影响因素分析[J]. 临床输血与检验, 2021, 23(2): 156-162.
[2]	李晓洁, 慈雪萍, 张俊. 血清CEA、CA125联合CA199对晚期肝内胆管细胞癌患者预后的预测作用[J]. 临床输血与检验, 2020, 22(4): 434-439.
[3]	马洁, 孙明, 钱广兵. 同型半胱氨酸对急性心力衰竭患者预后的相关性分析[J]. 临床输血与检验, 2020, 22(4): 440-443.
[4]	王海妮, 陈安青. 血清IFN-γ、IL-2、EGF预测鼻咽癌患者放疗敏感性和预后的相关性分析[J]. 临床输血与检验, 2020, 22(3): 300-304.
[5]	饶楚炳. 血糖波动对急性冠脉综合征患者近期主要心血管不良事件的预测价值[J]. 临床输血与检验, 2020, 22(2): 206-210.
[6]	金梅, 马丹冬. 血清丙酸对感染性休克早期诊断及预后的评估价值[J]. 临床输血与检验, 2020, 22(1): 58-63.
[7]	魏世刚, 曾光群, 彭倩, 陈艳. 有丝分裂原活化蛋白激酶对HER-2阳性乳腺癌化疗疗效考核价值[J]. 临床输血与检验, 2020, 22(1): 77-81.
[8]	石琼梅, 惠朝晖, 张永顶, 龙国海. 血清降钙素原联合血小板平均体积检测对急性胰腺炎的病情预测价值[J]. 临床输血与检验, 2020, 22(1): 86-88.
[9]	常人亮, 王蓓, 胡良俊, 万玲玲, 李明. 外周血淋巴/中性粒细胞比值及淋巴/单核细胞比值对鼻咽癌患者预后的评估^*[J]. 临床输血与检验, 2019, 21(6): 630-632.
[10]	黄革, 黎卓辉, 郑有为, 吴际, 刘胜男. 广东地区中国型^Gγ⁺（^Aγδβ）⁰地中海贫血的基因鉴定及分析[J]. 临床输血与检验, 2019, 21(5): 465-467.
[11]	陈莉, 常文娇, 戴媛媛, 鲁怀伟. 10例布鲁氏菌病临床及实验室特征分析^*[J]. 临床输血与检验, 2019, 21(4): 421-423.
[12]	王云洁, 赵绍杰. MicroRNA-31表达与老年女性卵巢癌患者应用紫杉醇联合顺铂化疗的疗效及预后关系的研究*[J]. 临床输血与检验, 2019, 21(3): 236-238.
[13]	罗立, 冯锦红, 孔刘莎, 王迪生. β-catenin和cadherin蛋白联合血尿酸检测对DN预后的评估[J]. 临床输血与检验, 2019, 21(2): 180-183.
[14]	张锐东,张志发,李军. 输血相关急性肺损伤的危险因素及预后分析[J]. 临床输血与检验, 2018, 20(4): 368-370.
[15]	周银娣,沈继录. 某教学医院三年间铜绿假单胞菌临床特征与耐药趋势分析*[J]. 临床输血与检验, 2018, 20(4): 399-401.